AGN: ALLERGAN INC Profile

Ticker

Advertisement

Choose a Broker

Dynamic view of the market

U.S. Markets open in 5 hrs, 21 mins

Symbol	Value	Change	Percentage Change
DJIA	11,384.21	152.25	1.36%
NASDAQ	2,294.44	51.12	2.28%
S&P 500	1,273.70	21.39	1.71%

ALLERGAN INC

AGN

Stock price

52.29 1.12 2.19%

as of 04:03 PM EDT on 07/08/2008 in USD (NYSE Delay: 20 mins.)
Extended Hours

52.29 0.00 0.00%

as of 04:59 PM EDT on 07/08/08

Analyst Consensus

Buy
Analyst Consensus

Strong Buy

Buy

Hold

Sell

Strong Sell
- Add to Portfolio
- Add to Alerts
Discuss: AGN

Insightful information about industries, companies, and the people who lead them.

Learn More.

2007 Sales	2007 Sales Growth	2007 Net Income	2007 Employees
$3,938,900,000	28.6%	$499,300,000	7,886

Key Executives: AGN

Name	Title	Officer Since
David E. I. Pyott	CEO	1/1/98
Jeffrey L. Edwards	CFO	-
Douglas S. Ingram, Esq.	Chief Administrative Officer	-
James F. Barlow	Chief Accounting Officer	-
F. Michael Ball	President	-
Gavin S. Herbert	Director/Founder/Other Corporate Officer	1/1/50
Prof. Trevor M. Jones, Ph.D.	Director	7/27/04
Dr. Deborah L. Dunsire, M.D.	Director	12/4/06

View All Key Executives

David E.I. Pyott, 54, has been our Chief Executive Officer since January 1998 and in 2001 became Chairman of our board. Mr. Pyott also served as our President from January 1998 until February 2006. Previously, he was head of the Nutrition Division and a member of the executive committee of Novartis AG, a publicly-traded company focused on the research and development of products to protect and improve health and well-being, from 1995 until... View Full Profile

David E. I. Pyott

Gavin S. Herbert, 75, is our founder and has served as Chairman Emeritus since 1996. He had been Chairman of our board since 1977 and also served as our Chief Executive Officer from 1977 to 1991. Prior to that, Mr. Herbert had been our President and Chief Executive Officer since 1961. He is Chairman and Founder of Regenesis Bioremediation Products, Inc., a privately-held bioremediation company formed in 1994. Mr. Herbert is a life trustee of the... View Full Profile

Gavin S. Herbert

Trevor M. Jones, Ph.D., 65, served as the Director General of the Association of the British Pharmaceutical Industry, or ABPI, an association representing the interests of approximately 75 British and international pharmaceutical companies, from 1994 through his retirement in August 2004. From 1987 to 1994, Prof. Jones was a main board director at Wellcome plc, a major healthcare business that merged with GlaxoSmithKline plc, where he was... View Full Profile

Prof. Trevor M. Jones, Ph.D.

Deborah Dunsire, M.D., 45, has served as President and Chief Executive Officer of Millennium Pharmaceuticals, Inc., a publicly-traded pharmaceutical company, since July 2005. Prior to joining Millennium Pharmaceuticals, Dr. Dunsire was Senior Vice President, Head of North American Oncology Operations from July 2000 to July 2005, and Vice President, Oncology Business Unit from August 1996 to June 2000, of Novartis AG, a publicly-traded company... View Full Profile

Dr. Deborah L. Dunsire, M.D.

Herbert W. Boyer, Ph.D., 71, is a founder of Genentech, Inc., a publicly-traded biotechnology company, and has been a director of Genentech since 1976. He served as Vice President of Genentech from 1976 through his retirement in 1991. Dr. Boyer, a Professor of Biochemistry at the University of California at San Francisco from 1976 to 1991, demonstrated the usefulness of recombinant DNA technology to produce medicines economically, which laid the... View Full Profile

Dr. Herbert W. Boyer, Ph.D.

Russell T. Ray, 60, has served as a Partner of HLM Venture Partners, a private equity firm that provides venture capital to health care information technology, health care services and medical technology companies, since September 2003. Mr. Ray was Founder, Managing Director and President of Chesapeake Strategic Advisors, a firm specializing in providing advisory services to health care and life sciences companies, from April 2002 to August 2003.... View Full Profile

Russell T. Ray

Stephen J. Ryan, M.D., 67, has served as President of the Doheny Eye Institute since 1987 and as the Grace and Emery Beardsley Professor of Ophthalmology at the Keck School of Medicine of the University of Southern California since 1974. Dr. Ryan was Dean of the Keck School of Medicine and Senior Vice President for Medical Care of the University of Southern California from 1991 through June 2004. Dr. Ryan is a Member of the Institute of Medicine... View Full Profile

Dr. Stephen J. Ryan, M.D.

Louis J. Lavigne, Jr., 59, has served as a management consultant in the areas of corporate finance, accounting and strategy since March 2005. Prior to that, Mr. Lavigne served as Executive Vice President and Chief Financial Officer of Genentech, Inc., a publicly-traded biotechnology company, from March 1997 through his retirement in March 2005. Mr. Lavigne joined Genentech in July 1982, was named Controller in 1983 and, in that position, built... View Full Profile

Louis J. Lavigne, Jr.

Robert A. Ingram, 65, has served as Vice Chairman Pharmaceuticals of GlaxoSmithKline plc, a publicly-traded pharmaceutical company, since January 2003. Mr. Ingram was the Chief Operating Officer and President, Pharmaceutical Operations of GlaxoSmithKline plc from January 2001 through his retirement in January 2003. Prior to that, he was Chief Executive Officer of Glaxo Wellcome plc from October 1997 to December 2000 and Chairman of Glaxo Wellcome... View Full Profile

Robert A. Ingram

Michael R. Gallagher, 62, was Chief Executive Officer and a Director of Playtex Products, Inc., a publicly-traded personal care and consumer products manufacturer, from July 1995 through his retirement in December 2004. Prior to that, Mr. Gallagher was Chief Executive Officer of North America for Reckitt & Colman plc, a consumer products company based in London. Mr. Gallagher was President and Chief Executive Officer of Eastman Kodak's subsidiary... View Full Profile

Michael R. Gallagher

Leonard D. Schaeffer, 62, is currently a Senior Advisor to TPG (formerly Texas Pacific Group), a private equity firm. Mr. Schaeffer served as Chairman of the board of directors of WellPoint, Inc., an insurance organization created by the combination of WellPoint Health Networks Inc. and Anthem, Inc., which owns Blue Cross of California, Blue Cross and Blue Shield of Georgia, Blue Cross and Blue Shield of Missouri, Blue Cross and Blue Shield of... View Full Profile

Leonard D. Schaeffer

Dr. Whitcup has been Executive Vice President, Research and Development since July 2004. Dr. Whitcup joined Allergan in January 2000 as Vice President, Development, Ophthalmology. In January 2004, Dr. Whitcup became Allergan's Senior Vice President, Development, Ophthalmology. From 1993 until 2000, Dr. Whitcup served as the Clinical Director of the National Eye Institute at the National Institutes of Health. As Clinical Director, Dr. Whitcup's... View Full Profile

Scott M. Whitcup, M.D.

Mr. Ingram has been Executive Vice President, Chief Administrative Officer, General Counsel and Secretary, as well as our Chief Ethics Officer, since October 2006. From October 2003 through October 2006, Mr. Ingram served as Executive Vice President, General Counsel and Secretary, as well as our Chief Ethics Officer. Prior to that, Mr. Ingram served as Corporate Vice President, General Counsel and Secretary, as well as our Chief Ethics Officer,... View Full Profile

Douglas S. Ingram, Esq.

Mr. Edwards has been Executive Vice President, Finance and Business Development, Chief Financial Officer since September 2005. Prior to that, Mr. Edwards was Corporate Vice President, Corporate Development since March 2003 and previously served as Senior Vice President Treasury, Tax, and Investor Relations. He joined Allergan in 1993. Prior to joining Allergan, Mr. Edwards was with Banque Paribas and Security Pacific National Bank, where he held... View Full Profile

Jeffrey L. Edwards

Mr. Ball has been President, Allergan since February 2006. Mr. Ball was Executive Vice President and President, Pharmaceuticals from October 2003 until February 2006. Prior to that, Mr. Ball was Corporate Vice President and President, North America Region and Global Eye Rx Business since May 1998 and prior to that was Corporate Vice President and President, North America Region since April 1996. He joined Allergan in 1995 as Senior Vice... View Full Profile

F. Michael Ball

Mr. Diradoorian has served as Allergan's Executive Vice President, Global Technical Operations since February 2006. From April 2005 to February 2006, Mr. Diradoorian served as Senior Vice President, Global Technical Operations. From February 2001 to April 2005, Mr. Diradoorian served as Vice President, Global Engineering and Technology. Mr. Diradoorian joined Allergan in July 1981. Prior to joining Allergan, Mr. Diradoorian held positions at... View Full Profile

Raymond H. Diradoorian

Mr. Barlow has been Senior Vice President, Corporate Controller since February 2005. Mr. Barlow joined Allergan in January 2002 as Vice President, Corporate Controller. Prior to joining Allergan, Mr. Barlow served as Chief Financial Officer of Wynn Oil Company, a division of Parker Hannifin Corporation. Prior to Wynn Oil Company, Mr. Barlow was Treasurer and Controller at Wynn's International, Inc., a supplier of automotive and industrial... View Full Profile

James F. Barlow

Dawn Hudson, 50, served as President and Chief Executive Officer of Pepsi-Cola North America, or PCNA, the multi-billion dollar refreshment beverage unit of PepsiCo, Inc. in the United States and Canada from March 2005 until November 2007. From May 2002 through March 2005, Ms. Hudson served as President of PCNA. In addition, Ms. Hudson served as Chief Executive Officer of the PepsiCo Foodservice Division from March 2005 to November 2007. Prior to... View Full Profile

Dawn E. Hudson

Top Competitors: AGN

View Detailed Competitors Chart

Insider Trends: AGN
Sentiment for AGN is POSITIVE
- 0M
- 2M
- 4M
- 6M
- Market Value of Insider Sales
- Market Value of Insider Purchases
Total dollar value of all insider purchases and sales over 12 months
View All Insider Sentiment

Insider Transactions: AGN

Date	Name	Shares	Transaction Type	Market Value
05/27/08	LAVIGNE LOUIS J JR	3,600	Stock Gift	$0.00
05/27/08	SCHAEFFER LEONARD DAVID	3,600	Stock Gift	$0.00
05/27/08	BOYER HERBERT W	3,600	Stock Gift	$0.00

View All Insider Activity

Ownership Breakdown : AGN

Large Block Holder Type	Number
Institutions	628.00
Mutual Fund	1,315.00
Other Major	18.00

Full Details

Indices : AGN

Symbol	Name	Last Trade	Change
$RUI.X	Russell 1000 Index	696.61	11.73 1.71%
$INX	S&P 500 Index	—	——%

View all Indices that include AGN

Short Interest Volume: AGN

Data as of 6/10/08

Current Short Interest Shares	1.10 B
Current Short Interest Ratio	3.30
Float	304.11 M

Short Interest as % of Float	2.90
Average Daily Volume	2.48 M
Outstanding Shares	305.00 M

Full Details

SEC Filings: AGN

Accepted Date	Description
07/02/2008	SEC Filing: Insider Buy/Sell
07/02/2008	SEC Filing: Insider Buy/Sell
07/02/2008	SEC Filing: Insider Buy/Sell

View all SEC Filings

Get Profile Details for:

- Help & Feedback

Market Movers

Related Resources

My Portfolios

AOL Real-Time Streaming Quotes

ALLERGAN INC

AGN

Stock price

52.29 1.12 2.19%

as of 04:03 PM EDT on 07/08/2008 in USD (NYSE Delay: 20 mins.)
Analyst Consensus
- Strong Buy
- Buy
- Hold
- Sell
- Strong Sell
- Add to Portfolio
- Add to Alerts
Discuss: AGN

Quote Search Search the Web Search

More in Money & Finance
- Money
- Earnings
- Tech News
- Stock Screener
- Banking
- Checking Account
- Savings Account
- Credit Cards
- Credit Reports
- Identity Theft
- Debt Management
- Loans
- Auto Loan
- Personal Loans
- Mortgages
- Refinancing
- Taxes
- Online Tax Filing
- Tax Advice
- Tax Basics
- Tax Forms
- Audit
- Tax Credit
- Tax Deduction
- AMT
- Small Business
- BloggingStocks
- BloggingBuyouts
- Luxist
- TUAW
- DJIA
- Dow Jones Industrial Average
More Stock Research
Notices and Terms: Confirm all data with your broker before trading.

Quote data provided by Interactive Data. Historical prices provided by Prophet. Company Profile provided by Hoovers. Executive data and Industry/Sector information provided by Morningstar Inc. Earnings, Ownership, Financial Statement, Insider Trading, Conference Call schedules and SEC Filing information provided by Thomson Financial.

The ALLERGAN INC profile at AOL Money & Finance provides you with all the agn investing information you need. Reference AOL Money & Finance before you make your next investment!

© 2008 AOL LLC. All Rights Reserved.

AOL@Money © 2008 AOL LLC. All Rights Reserved.

Live Updates:

Ticker

Dynamic view of the market

ALLERGAN INC

AGN

Stock price

Extended Hours

Analyst Consensus

ALLERGAN INC Profile

Key Executives: AGN

Top Competitors: AGN

Insider Trends: AGN

Insider Transactions: AGN

Ownership Breakdown : AGN

Indices : AGN

Short Interest Volume: AGN

SEC Filings: AGN

Quote Details

Classic Chart

Advanced Chart BETA

Real-Time Headlines

Message Boards

Profile

Earnings Analysis

Event Calendar

Financials

Market Movers

Related Resources

ALLERGAN INC

AGN

Stock price

Analyst Consensus

More in Money & Finance

More Stock Research